Cancer Genetics (NASDAQ:CGIX) Now Covered by Analysts at initiated coverage on shares of Cancer Genetics (NASDAQ:CGIXFree Report) in a research note published on Monday morning. The firm issued a sell rating on the stock.

Cancer Genetics Price Performance

Shares of CGIX stock opened at $0.16 on Monday. Cancer Genetics has a 52-week low of $2.11 and a 52-week high of $17.50. The firm has a market capitalization of $645,838.50, a PE ratio of -0.08 and a beta of 2.72.

Cancer Genetics Company Profile

(Get Free Report)

Vyant Bio, Inc is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson’s Disease.

Featured Articles

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.